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The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics,
in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the
recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial,
strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach:
direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events
and/or eliminate the transplanted cells and their progeny.population, but given that proposed therapies using embryonic
stem cells (ESCs) and induced pluripotent stem cells (iPSCs)
will likely be conducted with differentiated, yet still multipotent
progeny, the example is highly relevant.
Based on the risks of therapeutic transplantation of wayward
pluripotent stem cells and their progeny, strategies need to be
adapted to alter the risk/benefit ratio markedly in favor of stem
cell therapy. While positive selection of differentiated cells and/
or negative selection of undifferentiated cells prior to transplan-
tation reduce the risks (Hodges et al., 2007; Li et al., 2001;
Gordon, 2008; Hentze et al., 2007), given the inherent nature of
pluripotency, additional strategies must be incorporated into
the transplant strategy to ensure that therapeutic uses of plurip-
otent stem cells will be safe. In the context of the risks, strategies
must be developed to control and/or eliminate wayward stem
cells and/or their progeny. For example, the transplanted cells
could be treated with mitomycin C, an agent that permanently
arrests cell division. While mitomycin C is not approved for clin-
ical use, development of new agents with similar properties but
fewer risks might be useful. If the transplanted cells are not
immune compatible, and immunosuppression is used to achieve
immune tolerance, a strategy to eliminate transplanted cells is to
remove the immunosuppression, allowing the immune system to
destroy the transplanted cell progeny. This approach would
likely result in deletion of the transplant, albeit with possible
collateral damage to adjacent tissues.
In addition to measures applied ‘‘after the fact,’’ it should be
possible to develop ‘‘failsafe’’ strategies using ex vivo genetic
targeting of the therapeutic cells prior to transplantation, a prom-
inent strategy under development. Given the decades of experi-
ence within the gene therapy field, we offer this Perspective to
present relevant insights and caveats to be considered when
applying genetic modification to pluripotent-stem-cell-derived
therapeutics. The use of gene transfer as a means to control
wayward stem cell progeny is conceptually similar to using
gene therapy to treat cancer (Crystal, 1999; Cross and
Burmester, 2006; Li et al., 2005; Park et al., 2008b; Rein et al.,
2006). However, a major difference distinguishes the two situa-
tions and offers a distinct advantage for stem cell therapy appli-
cations. That is, whereas the cancer gene therapist faces the
challenge of delivering the therapeutic gene to treat a preexistingPluripotent stem cells have the potential to offer an unlimited
source of normal differentiated cells to enable diseased tissues
to regain normal function (Mayhall et al., 2004; Rippon and
Bishop, 2004; Keller, 2005). This remarkable potential is based
on the self-renewal capacity of pluripotent stem cells and their
ability to differentiate into all tissues of the three germ layers
(Evans and Kaufman, 1981; Martin, 1981; Thomson et al.,
1998; Fischbach and Fischbach, 2004; Rippon and Bishop,
2004; Keller, 2005). However, translating the regenerative poten-
tial of pluripotent stem cells to treat human disease faces many
challenges, including the design of mechanisms that will allow
for control over the transplanted cells. With the recent FDA
approval to test the use of human embryonic stem cells for spinal
cord injury treatment (Couzin, 2009), translation of pluripotent
stem cells to the clinic is rapidly becoming a reality. In the context
of the potential risks posed by wayward pluripotent stem cells, it
is the responsibility of the community of stem cell scientists and
clinicians to develop strategies to control our therapies after
transplantation. In this discussion, we focus on candidate strat-
egies based on genetic modification of the pluripotent stem cells
prior to transplantation.
Conventional pharmaceuticals, recombinant proteins and
monoclonal antibodies all have a finite half-life. In contrast, the
inherent property of stem cell pluripotency confers indepen-
dence to the therapeutic agent, and the stem cell therapist has
no control over what the cells do after transplantation. Among
the risks associated with pluripotent-stem-cell-derived trans-
plants are cells that differentiate incorrectly, are inappropriately
localized, produce progeny in excess numbers, or in the worst
case, form tumors. What can be done if some of the stem cells
differentiated to dopaminergic neurons and transplanted to the
CNS to treat Parkinson’s disease dedifferentiate to beating heart
muscle, or if stem cells differentiated into pancreatic islet cells
and transplanted to the liver lose control of insulin production
or are inadvertently localized in the brain? What can we do if
stem-cell-derived transplants transform into malignant cells?
These issues are not theoretical, as illustrated by the recent
report of a glioneuronal tumor derived from fetal neural stem cells
administered to a patient with ataxia telangiectasia 4 years after
the initial therapy (Amariglio et al., 2009). In this case, the trans-
ferred population was not derived from a cultured pluripotentCell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 289
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ex vivo access to the therapeutic cells prior to transplantation.
For some strategies, the proactive therapy can be designed to
prevent untoward biologic events, such as reversion of trans-
planted cells to a pluripotent state. Alternatively, the most direct
genetic engineering strategy to control wayward stem cell
progeny is to eliminate the wayward cells. Our focus will be
on ESCs and iPSCs, but similar concepts can be adapted for
application to other stem cell populations. For convenience,
we will refer to all of the transplanted populations as ‘‘stem cell
progeny.’’
Origins of Pluripotent Stem Cells
All pluripotent cells are characterized by the ability to differen-
tiate into derivatives of all three germ layers, combined with
the capacity to proliferate over prolonged periods of culture
while remaining undifferentiated (Evans and Kaufman, 1981;
Martin, 1981; Thomson et al., 1998; Fischbach and Fischbach,
2004; Gordon, 2008; Keller, 2005; Rippon and Bishop, 2004).
ESCs are derived from the blastocyst (70 to 100 cells), late
morula (10 to 30 cells), or single blastomere stage (8 cells) of
the embryo within 5 to 6 days after fertilization (Thomson et al.,
1998; Strelchenko et al., 2004; Klimanskaya et al., 2006; Zhang
et al., 2006).Whilemany human ESC lines have been established
(Strulovici et al., 2007), the use of ESCs as therapeutics is
confounded by the issue that, in the absence of histocompati-
bility between therapeutic cells and recipient, immunosuppres-
sion will be required to prevent the host from rejecting the
transplanted cells (Fairchild et al., 2004; Martin et al., 2005). To
circumvent this issue, several approaches have been used to
establish patient-specific pluripotent stem cells, including
somatic cell nuclear transfer (Hochedlinger and Jaenisch,
2002, 2006), cell fusion (Tada et al., 2001; Cowan et al., 2005),
and transdifferentiation of germ cells (Durcova-Hills et al.,
2008). The newest strategy is to genetically reprogram differen-
tiated cells from the potential transplant recipient using pluripo-
tency-required transcription factors (Nishikawa et al., 2008).
These ‘‘induced pluripotent stem cells’’ (iPSCs) were initially
created by reprogramming mouse fibroblasts with octamer-
binding transcription factor-3/4 (Oct3/4), SRY-related high-
mobility-group (HMG) box protein-2 (Sox2), c-Myc, and Krup-
pel-like factor-4 (Klf4) (Takahashi and Yamanaka, 2006). Mouse
iPSCs derived in this fashion have all of the characteristics of
ESCs—with expression of ESC markers, similar gene-expres-
sion profiles, and the ability to form teratomas—and contribute
to multiple different cell types in chimeric animals (reviewed in
Yamanaka, 2008). An alternative combination used to reprogram
either mouse or human differentiated cells to iPSCs is the four-
factor set of Oct3/4, Sox2, Lin28, and Nanog, and subsequently
strategies have been successful in the absence of the oncogene
c-Myc with only Oct3/4, Sox2, and Klf4 and even with only Oct3/
4 and Sox2 (Lowry et al., 2008; Maherali et al., 2007; Okita et al.,
2007; Takahashi et al., 2007; Wernig et al., 2007; Yu et al., 2007;
Nakagawa et al., 2008; Nishikawa et al., 2008; Park et al., 2008a;
Wernig et al., 2008). Subsequently, Kim et al. (2009) reported that
exogenous expression of a single gene, Oct4, is sufficient to
generate iPSCs from adult mouse neural stem cells. Although
gene-expression profiles of human iPSCs and human ESCs
are closely correlated, there are some distinctions, as well as290 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.differences observed across different iPSC clones and among
iPSCs and human ESC lines (Yu et al., 2007; Lowry et al., 2008).
Risks of Wayward Pluripotent Stem Cells
Because of the potential of pluripotent stem cells for unlimited-
self renewal, ability to differentiate into any cell type, and poten-
tial to develop tumors, the pluripotent stem cell cannot itself be
used as an in vivo therapeutic. Rather, the therapeutic useful-
ness of the pluripotent stem cell is as an ex vivo factory to
produce progenitors of differentiated cells or the final differenti-
ated cells per se. However, there are also risks to using the cell
progeny of pluripotent stem cells (Figure 1).
Risk for Tumor Formation
Of all of the risks of stem cell therapy, the most serious, and the
risk that has gotten the most attention, is the risk for tumor
formation (Vogel, 2005; Oh and Choo, 2006; Hentze et al.,
2007; Addis et al., 2008; Corsten and Shah, 2008). The concept
that transplanted stem cells may result in tumor formation is not
new. One criteria that defines pluripotent stem cells is their
capacity to form teratomas when transplanted into immunosup-
pressed mice (Martin, 1981; Thomson et al., 1998; Amit and
Itskovitz-Eldor, 2002; Blum and Benvenisty, 2008; Carpenter
et al., 2003; Fischbach and Fischbach, 2004; Gordon, 2008).
Teratomas contain differentiated derivatives of all three embry-
onic germ layers and are considered benign, as they do not
invade adjacent tissues or metastasize. The major risk for tera-
tomas is their potential damage as space-occupying lesions
that interfere with organ function. More serious are teratocarci-
nomas, malignant tumors thought to arise from an embryonal
carcinoma cell, the malignant equivalent of a pluripotent stem
cell with genetic abnormalities (Stevens, 1958; Kleinsmith and
Pierce, 1964; BlumandBenvenisty, 2008; Brickman andBurdon,
2002). Teratocarcinomas are associated with the potential for
local invasion and distant metastasis. Karyotypic changes
Figure 1. The Pluripotent Stem Cell Is the Factory to Generate the
Progenitor and Differentiated Cells to Be Transplanted for
Therapeutic Purposes
The risks of the various cell populations are indicated. The example is of differ-
entiated cardiac muscle, but the paradigm holds for any differentiated cell
type.
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embryonic carcinoma cells, with abnormalities in chromosomes
12, 17, and X, and thus there is a small, but finite, risk of plurip-
otent stem cells generating teratocarcinomas (Strulovici et al.,
2007; Harrison et al., 2007; Draper et al., 2004; Blum and Benve-
nisty, 2008).
There is also the risk of differentiated progeny of stem cells
generating tumors. In this regard, by definition, the fetus is
derived from the progeny of pluripotent stem cells and, despite
all of the natural built-in controls, fetal-derived malignancies
can develop in otherwise normal pregnancies, including neuro-
blastoma, melanoma, leukemia, CNS tumors, and teratomas
(Tolar andNeglia, 2003). Among the best-documented examples
of transplanted stem cells being the origins of malignancy in the
recipient are those of hematopoietic stem cell transplantation re-
sulting in donor-stem-cell-based leukemias (Greaves, 2006).
Leukemias develop more commonly when the hematopoietic
stem cells are derived from umbilical cord blood than from
bone marrow or blood (Greaves, 2006), suggesting that more
immature stem/progenitor cells carry a greater risk for genera-
tion of malignancy (Amariglio et al., 2009). There are also
numerous examples of donor-derived human bone marrow cells
contributing to solid organ cancers developing after bone
marrow transplantation (Barozzi et al., 2003; Avital et al., 2007;
Golfinopoulos et al., 2009).Whether these bone-marrow-derived
cells are responsible for the tumor or contribute to a microenvi-
ronment that supports tumor growth is not clear, but these
examples highlight the potential risks of using stem/progenitor
cells as therapies (Dubernard et al., 2008; Roorda et al., 2009).
In regard to transplants of non-marrow-derived stem cells, the
report by Amariglio and colleagues (Amariglio et al., 2009)
describes the development of a brain tumor derived from neural
stem cells used to treat ataxia telangiectasia. The patient,
a 13-year-old boy, received neural stem cells on two occasions,
at age 9 and 12. Analysis of the tumor led to the conclusion that it
was multiclonal, derived from the neural stem cells obtained
from at least two fetuses.
To avoid the generation of teratomas and teratocarcinomas,
the strategy for therapeutic use of pluripotent stem cells is not
to transplant pluripotent stem cells, but rather to induce the
in vitro differentiation of the pluripotent stem cells to progenitors
of mature cells or the final differentiated cells, followed by selec-
tion for the progenitors/differentiated cells and subsequent
transplantation of the purified populations (Lerou and Daley,
2005; O’Connor and Crystal, 2006; Hodges et al., 2007).
However, even with stringent strategies of positive and negative
selection prior to transplant (Hentze et al., 2007), even a few
contaminating undifferentiated cells within a pluripotent-stem-
cell-derived transplant may be sufficient to result in teratoma
formation (Addis et al., 2008; Kleinsmith and Pierce, 1964;
Lawrenz et al., 2004). Mouse ESC-derived differentiated cells
have been transplanted into a variety animal models of human
disease, including diabetes, neurodegenerative diseases, liver
disease, and muscular dystrophy, with evidence of disease
correction (Ben-Hur et al., 2004; Asahina et al., 2006; Docherty
et al., 2007; Hedlund et al., 2007; Price et al., 2007). However,
despite the fact that the ESCs were differentiated pretransplan-
tation, teratoma formation was observed in as many as 60% of
transplanted animals (Fujikawa et al., 2005; Blum and Benve-nisty, 2008; Darabi et al., 2008). With current technology, it is
very difficult to ensure that the transplanted population is entirely
free of pluripotent stem cells. The number of undifferentiated
mouse ESCs required to form a tumor is extremely low; as few
as two mouse ESCs mixed with 2 3 106 somatic fibroblasts
resulted in teratoma formation in >60% of cases (Lawrenz
et al., 2004), and a single mouse teratocarcinoma cell can give
rise to secondary teratocarcinomas (Kleinsmith and Pierce,
1964). In the context of these observations, the FDA-approved
Geron spinal cord injury trial will need to be monitored carefully
for possible low levels of contaminating ESCs.
While the induction of teratomas from pluripotent stem cells
contaminating the transplant is the most likely tumor-related
risk of stem cell therapy, there is also the risk of transferred cells
reverting to pluripotency, or malignant transformation of the
pluripotent-stem-cell-derived progenitors and/or differentiated
cells (Figure 1). iPSC-derived transplants may introduce addi-
tional risks, in that the pluripotency genes introduced into
somatic cells to generate iPSCs may increase the risk of uncon-
trollable growth in these cells and their progeny (Nishikawa et al.,
2008). The risk for these events can be reduced by careful
screening of the cells to be transplanted for chromosomal abnor-
malities, genome-wide single-nucleotide polymorphisms/copy
number variations, and genome-wide gene expression.
However, unknown risks of stem/progenitor cells generating
tumors may also come from the lack of normal developmental
controls provided by the local milieu in normal organ growth,
and/or from the stress placed on the transplanted cells by
growth factors used to promote stem/progenitor cell expansion
prior to transplantation.
Other Risks
Beyond tumor formation, other risks of stem cell therapy include
excess proliferation, inappropriate differentiation, improper
localization, and unsatisfactory function of the transplanted cells
or their progeny.
The risk for excess proliferation is not trivial, particularly if the
transplanted cells are progenitors that require proliferation to
differentiate in vivo. Although the numbers of progenitors to be
transplanted can be controlled, immature tissue progenitors
could produce excess progeny after their transfer. Even though
excessive growth may not lead to tumor formation, the resulting
cell mass could result in compression of adjacent normal struc-
tures or nonphysiological levels of cell function, which may
impact the function of the adjacent and distant tissues. This
risk is particularly relevant if the transplant provides potent medi-
ators (e.g., endocrine function) and thus low numbers of excess
differentiated cells in organs such as brain, retina, or heart could
significantly disrupt organ function (Freed et al., 2001; Addis
et al., 2008; Hentze et al., 2007). The underlying assumption is
that environmental cues from the organ receiving the transplant
will provide this control, but until the biology of organ-specific
stem cell/progenitor niches is fully understood, and strategies
are developed to control the location and environment provided
for the transplant, excess proliferation is a theoretical risk.
The risk for improper localization has been observed in murine
studies with populations of transplanted ESCs, in which the
transplanted cells and/or their progeny migrate to distant sites.
For example, following intramyocardial delivery of murine
ESCs, tumors derived from the ESCs were detected in the heart,Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 291
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2006). Inappropriate localization has also been observed with
transplanted neural progenitors, with the potential risk of
abnormal brain function, white and/or gray matter heterotopias,
and epilepsy (Gage, 2000; Roy et al., 2006). Skin carcinomas
have been identified that arose from donor cells of kidney trans-
plant recipients, suggesting that progenitor cells present in
a grafted kidney may migrate to skin, where they transform or
fuse to keratinocytes that undergo malignant transformation
(Aractingi et al., 2005). Finally, there are numerous examples in
the literature in which human donor bone marrow-derived
stem/progenitor cell genomes are found in differentiated
epithelia, hepatocytes, myocardiocytes, neurons, endometria,
endothelia, and mesenchymal cells (Korbling et al., 2002;
Okamoto et al., 2002; Quaini et al., 2002; Tran et al., 2003;
Weimann et al., 2003; Spyridonidis et al., 2004; Taylor, 2004;
Mattsson et al., 2004; Minami et al., 2005). Independent of
whether this donor contribution results from differentiation and/
or fusion, these examples point to the risks of improper localiza-
tion of stem/progenitor cell transplants.
Even when cells do differentiate appropriately into the relevant
tissue, and in the correct location, the functional output of those
cells may not be sufficient and/or appropriate to satisfy the ther-
apeutic need that necessitated the original transplant. For some
organs (e.g., liver), this defectmay not become a significant issue
other than failure of the transplant, but for other organs (e.g.,
heart, brain), such cells could evoke local dysfunction and may
obviate future transplant therapy. The primary strategy to
circumvent inappropriate differentiation and/or incomplete
cellular function following transplantation is to fully understand
the differentiation pathways involved, in order to ensure that
the biologic signals used to differentiate the pluripotent stem
cells are inclusive and function with fidelity (Keller, 2005).
Strategies to Provide Control of Stem Cells
Posttransplantation
To maintain control of pluripotent stem cells and their progeny
posttransplantation, the cells to be transplanted can be geneti-
cally modified with genes that can provide the required control,
either by functioning to prevent adverse events (e.g., reversion
to pluripotency) or to eliminate cells that have gone awry. We
will first discuss the genetic strategies, and then additional
requirements that must be met to provide effective and safe
control.
Prevention of Adverse Events
Aside from the transfer of contaminating undifferentiated plurip-
otent cells, one of the greatest risks for adverse events following
stem cell transplantation is the reversion to pluripotency or dedif-
ferentiation by the transferred cells. This form of adverse event
should be preventable by modifying the pluripotent stem cells
or the progenitor/differentiated cells prior to administration with
genes that, when activated, will lead to their elimination. Other
adverse events, such as differentiated cells that lead to tumor
formation, excess proliferation, or unsatisfactory function require
elimination of the cells, as there is no one specific gene that will
prevent such adverse effects from occurring. Controlling
wayward progeny of pluripotent cells can only be achieved
with ‘‘reactionary’’ measures, rather than by employing a preven-
tative strategy.292 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.From the perspective of preventing outgrowth following rever-
sion to pluripotency, it should be possible to introduce a gene
that would be turned on only if this occurs, since pluripotency
requires expression of specific genes (Keller, 2005; Noggle
et al., 2005; Rippon and Bishop, 2004). There are two
approaches, both of which would be targeted to progenitor
and/or differentiated cells. First, the cells could be modified
with a constitutive promoter driving an antisense siRNA ormicro-
RNA targeted to a pluripotency gene such asOct4, Nanog, Sox2,
Klf4, c-Myc, or Lin28, all of which contribute to the reprogram-
ming of somatic cells into pluripotent stem cells (Nishikawa
et al., 2008). In this approach, if designed appropriately, the
expression of a critical pluripotency gene would also drive the
repressive regulatory RNA construct, and thus prevent final
reversion to a pluripotent state. Alternatively, the cells could be
modified to express a gene that would mediate destruction of
the cell (see below). However, to protect the transplanted cells
from this gene being expressed inappropriately, the gene would
have to be tightly controlled by a promoter that would be turned
on only if reversion to pluripotency occurred. This selectivity
could be accomplished by using promoters of the pluripo-
tency-required genes targeted by the antisense strategy. Since
several genes are required for pluripotency, there are several
available targets, and by using a combination of genes onemight
design ‘‘failsafe,’’ or redundancy, strategies. However, it is also
important to note that, while multiple genes contribute to the
induction and/or maintenance of the pluripotent state, several
of these potential safety gene targets are also expressed in
normal, nonpluripotent cells (i.e., c-Myc, Klf4, Sox2). Thus, in
setting a ‘‘trap’’ for potential reversion to pluripotency, one might
inadvertently cause the deletion of functional transplanted
progeny. Clearly, it is essential that appropriate promoter design
takes into account the relative risks and benefits to the trans-
ferred cells—both functional and wayward—and thus keeps
the health of the patient as the ultimate priority.
Elimination of Cells that Have Gone Awry
The most direct strategy, and likely the most broadly useful to
deal with all possible adverse events following stem cell trans-
plantation, is to genetically modify cells with genes that, when
active, mediate destruction of the transplanted cells or their
progeny. There are many way to accomplish this goal, but
because such genes are ‘‘genetic time bombs’’ lurking in the
cell, careful attention must be paid to how to control such genes,
i.e., the transferred gene will need to be turned ‘‘on’’ or ‘‘off’’ as
required. The promoter choices for controlling genes that in turn
could mediate control of stem cell transplants include the
following promoters: (1) constitutive, (2) cell specific, and (3)
inducible. Opting for one promoter over another will typically
depend on how the presence of wayward cells will be identified
and/or accessed following transplantation, on what specific
destructive mediators are to be utilized, and the level of
bystander risk that is acceptable in a given clinical situation
(Figure 2).
Constitutive promoters like the cytomegalovirus promoter/
enhancer or phosphoglycerate kinase promoter are commonly
used in gene transfer applications because they mediate sus-
tained, highly active expression in most cell types (Boshart
et al., 1985; Foecking and Hofstetter, 1986). However, this
strategy is applicable only where constitutive expression of the
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Facilitate Control of Potential Wayward
Pluripotent Stem Cells and Their Progeny
The vectors (retrovirus, lentivirus, or plasmid)
mediate integration of the expression cassette
into the pluripotent stem cell or its progeny de-
pending on the application. The expression
cassette contains two elements. One promoter
(constitutive, pluripotent, or regulated depending
on the need) regulates the ‘‘control’’ gene (pluripo-
tent antisense, enzyme prodrug, toxin or
apoptotic, or plasma membrane tag). The second
promoter regulates a gene used for selection (anti-
biotic based or a plasmamembrane tag). The stem
cell population that has been genetically modified
is then selected and transferred to the patient as
dictated by the therapeutic needs. If there is
a need to control a wayward stem cell population,
the promoter is activated and/or a prodrug admin-
istered, eliminating the wayward cells.cells is referred to as gene-directed enzyme prodrug therapy
(Kirn et al., 2002; Denny, 2004; Bonini et al., 2007). In the appli-
cation of this form of suicide gene therapy to stem cell therapy,
a gene that codes for an enzyme that converts an innocuous pro-
drug to a toxic drug would be delivered into the cells to be trans-
planted. When the prodrug is administered to the transplant
recipient, the enzyme expressed in the target cells converts
the prodrug into its active form that is toxic to the cell.
Analogous to strategies for stem cell transplantation, genes
coding for enzymes that convert prodrugs to cytotoxic drugs
have been used successfully to treat undesired alloreactivity in
the context of allogeneic hematopoietic stem cell transplantation
with more than 100 patients treated worldwide (Bonini et al.,
1997, 2007). This gene transfer approach is used to control the
graft versus host complications of the stem cell transplant asso-
ciated with donor T lymphocytes helping to treat the leukemia.
While the immune advantage provided by the donor T cells is
effective in controlling the malignancy, the donor T cells must
be suppressed if they also mediate graft versus host complica-
tions. To provide control over this complication, the donor
lymphocytes are genetically modified ex vivo prior to transplant
with a gene encoding an enzyme that will convert a nontoxic drug
to a toxic drug, alongwith a gene that permits ex vivo selection of
the genetically modified cells. If and when graft versus host
adverse reactions occur, the prodrug is administered, with
consequent depletion of the donor T lymphocyte pool.
Typically, when using gene-directed enzyme prodrug therapy
to treat cancer, it is preferable that the toxic drug product affects
both the cell expressing the enzyme and cells in the local milieu
(Portsmouth et al., 2007). This so-called ‘‘bystander’’ effect
leverages the therapy, killing not only the transplanted, modified
cells, but also surrounding cells of the recipient. While this
peripheral damage offers an advantage for in vivo cancer gene
therapy, when applied to regenerative medicine, all of the cells
that are potential targets would by design be genetically modi-
fied, and therefore, ‘‘bystander’’ effects could potentially cause
undesirable damage to normal tissue. However, the benefits of
gene-directed enzyme prodrug therapy are generally considered
to outweigh the toxic side effects, relative to other conventional
forms of cancer therapy, including radiation, chemotherapy, or
surgery (Hedley et al., 2007). Furthermore, it has been showngene used for control will not adversely affect the function of the
targeted cell. Another challenge is the phenomenon of promoter
shutdown, usually due to an epigenetic process accompanying
changes in cell physiology (Brooks et al., 2004).
Targeting Strategies. By contrast, cell-specific promoters
could be used that would evoke gene expression only in cells
where the control is needed, and the gene is expressed. This
approach may be useful for applications in which the utilized
gene cannot be constitutively ‘‘on.’’ For example, the expression
of toxic gene might be controlled by Oct4, a promoter that func-
tions only in pluripotent stem cells but not in the stem cell
progeny, turning ‘‘on’’ only if a progeny cell reverted to pluripo-
tency (Gerrard et al., 2005).
The ideal promoter strategy would be a promoter that can be
activated or shut off by an exogenous signal that is administered
to the patient. A number of these inducible promoters have been
developed and function remarkably well in culture and in exper-
imental animals, including promoters regulated by tetracycline,
cAMP, rapamycin, and steroid hormones (Hu and Davidson,
1988; Gossen and Bujard, 1992; Burcin et al., 1998; Ngan
et al., 2002; Rivera et al., 1996; Goverdhana et al., 2005; Curtin
et al., 2008). To date, there is no experience of using promoters
controlled by drugs in human gene transfer studies. The advan-
tage of promoters that depend on endogenous control is that
they are always available and do not require detection or inter-
vention by the stem cell therapist. In contrast, exogenous control
provides the stem cell therapist with maximal freedom of inter-
vention but requires detection and administration of a drug or
other therapy to activate the control mechanism. Exogenous
control also necessitates that the clinician have access to all
transferred cells, typically via the circulation. Systemic applica-
tion of the regulatory agent, however, does not allow for regional
targeting and thus may result in loss of the entire transplanted
progeny, including some presumably functional cells.
Selective Destruction. In parallel with the decision to utilize an
appropriately selective promoter, it is necessary to choose the
gene that will be used to mediate elimination of cells posttrans-
plant. These ‘‘suicide’’ genes can be categorized as drug
conversion, toxin or apoptosis, and tagging (Figure 2).
Conversion of Nontoxic Drugs to Toxic Drugs. The strategy of
converting nontoxic drugs to toxic drugs specifically in the targetCell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 293
Cell Stem Cell
PerspectiveTable 1. Control of Tumors Generated by Pluripotent StemCells GeneticallyModifiedwith a ProdrugEnzymePrior to Transplantationa
Gene Promoter Delivery method Outcome Reference
HSV-TK phosphoglycerate kinase plasmid elimination of subcutaneous teratomas Schuldiner et al., 2003
HSV-TK ubiquitin lentivirus prevention of teratoma formation Cao et al., 2006
HSV-TK ubiquitin lentivirus elimination of subcutaneous teratomas Cao et al., 2007
HSV-TK cytomegalovirus lentivirus elimination of teratomas in the flank and in the brain Jung et al., 2007
HSV-TK Oct4 knockin
to Oct4 locus
prevention of teratoma formation in a three-dimensional
culture
Hara et al., 2008
a For all of these strategies, the herpes simplex thymidine kinase gene was transferred to the pluripotent stem cell prior to in vitro or in vivo treatment
with the prodrug ganciclovir.294 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.Unlike HSV-TK and cytosine deaminase, which require actively
replicating cells for efficacy, suicide gene therapy with toxin
and proapoptotic genes is effective both on quiescent and
dividing cells. The E. coli-derived toxin 6-methylpurine is
membrane permeable, and in contrast to ganciclovir monophos-
phate, both dividing and nondividing cells are targeted in vitro
and in vivo (Gadi et al., 2003). Similarly, a number of gene prod-
ucts that stimulate apoptosis have been successfully adapted
for elimination of both dividing and nondividing cells not only
for treating hyperproliferative disorders, but also for targeting
cell types that have low proliferation rates (Fan et al., 1999).
Multiple Fas signaling molecules have been converted to artifi-
cial death switches that respond to nontoxic chemical inducers
of dimerization (CID) that target engineered CID-binding
domains in the target proteins (Fan et al., 1999; Spencer et al.,
1993). An example of the utility of this technology is prostate
cancer. Prostate adenocarcinomas grow very slowly and are
responsive to an adenovirus-delivered caspase-9-based artifi-
cial death switch (Xie et al., 2001). However, unlike gene-
directed enzyme prodrug therapy, where the therapist has
control over the toxicity and cell death by choosing when and
how long to administer the prodrug, applying gene therapy
with toxin or apoptotic genes to control stem cell transplants
has a significant risk, as it depends entirely on the promoter
controlling the gene, the product of which will induce cell death
if the promoter is leaky. In this context, if a strategy using a toxic
or apoptotic gene is employed to genetically modify pluripotent
stem cells or their progeny, extreme care must be given to
ensure that the transferred expression cassette is absolutely
‘‘off’’ and will express the genes following transplant only when
the appropriate signaling drug is administered.
Exploitation of Immune Response against Transplanted Cells.
An alternative method to eliminate transplanted cells is to capi-
talize on the endogenous immune response directed against
transplanted cells. One strategy shown to successfully work
for human tumors is to utilize innate immunity against a(1,3)gal-
actosyltransferase epitopes (Unfer et al., 2003). This gene is
mutated in humans, and therefore the recipient’s cells do not
express the agal moiety. Cells modified to express a(1,3)galac-
tosyltransferase will be recognized by antibodies specific for
cell surface agal epitopes eliciting complement-mediated
hyperacute graft rejection and antibody-dependent cell-medi-
ated cytotoxicity. This strategy, in combination with human
telomerase reverse transcriptase promoter, was used to ablate
undifferentiated human ESCs (Hewitt et al., 2007). Another
strategy to enable targeted destruction of pluripotent cells onlythat normal differentiated cells, e.g., in the brain, exist in a post-
mitotic state and thus can resist multiple forms of toxicity (Miletic
et al., 2007). To ensure a ‘‘surgical strike’’ therapy that impacts
only the intended cellular targets, it would be preferable to use
prodrug strategies in which the toxic drug only has access to
cells that have been genetically premodified.
The genes encoding enzymes used to convert prodrugs into
cytotoxic drugs include enzymes of nonmammalian origin, which
are only present in the cells that have been genetically modified,
and enzymes of human origin, which are not immunogenic but
are likely to be expressed in various host cell types, and thus
are less specific to the genetically modified cells (Portsmouth
et al., 2007). The most thoroughly studied nonmammalian gene
is that coding for herpes simplex virus thymidine kinase (HSV-
TK), which converts the prodrug ganciclovir into a cytotoxic
metabolite (Niculescu-Duvaz and Springer, 2004). Gene therapy
with HSV-TK has been used in several clinical trials as a cancer
therapy (Bonini et al., 1997, 2007), and there are several studies
demonstrating successful use of transfer of the HSV-TK gene
into pluripotent stem cells prior to transplantation, enabling
both tumor prevention and ablation of tumors (Table 1). Other
examples of suicide gene therapy using genes coding for
enzymes that convert prodrugs to toxic drugs include bacterial
cytosine deaminase (converts cytosine arabinoside to the cyto-
toxic monophosphate form), human b-glucuronidase (converts
HM-1826 to the cytotoxic doxorubicin), and human carboxyles-
terase (converts irinotecan to the cytotoxic SN-38). Detailed lists
of the genes used for enzyme/prodrug suicide gene therapy are
available in several reviews (Kirn et al., 2002; Niculescu-Duvaz
and Springer, 2004; Portsmouth et al., 2007).
Toxins and Apoptotic Genes. Another form of ‘‘suicide’’ gene
therapy uses genes encoding toxins or components of the
apoptosis pathway. When expressed, the genes from either
approach induce cell death, albeit by different mechanisms.
Examples of toxin genes used in experimental models are Shiga
toxin A1 (a toxin produced by Shigella dysenteriae) and Pseudo-
monas exotoxin A (a toxin produced by Pseudomonas aerugi-
nosa), both of which are potent inhibitors of protein synthesis
(Yerushalmi et al., 2000; Bonini et al., 2007; Denny, 2004;
Nakayama et al., 2005). Several genes that induce apoptosis
have been used to eliminate cancer cells, including those encod-
ing Fas ligand, Fas, FADD, caspase-3, caspase-8, caspase-9,
p53, p33ING1, p73a, Bax, Apaf-1, IkappaBdN, Bcl-2, Bcl-x,
and NBK (Liu et al., 1994; Kock et al., 1996; Shinoura et al.,
1998, 1999, 2000a, 2000b, 2000c, 2001b, 2001a; Arafat et al.,
2000; Shinoura and Hamada, 2003; Naumann et al., 2003).
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agal gene.
Tagging Cells for Destruction. One strategy unique to ex vivo
gene therapy, and thus relevant to stem cell transplant applica-
tions, is that a gene can be transferred to the cells to be
transplanted that confers a ‘‘tag’’ that allows in vivo homing of
therapies specifically to the tagged cell (Bonini et al., 1997;
Introna et al., 2000; Koehne et al., 2000; Robinet et al., 2005;
Sauce et al., 2002; Tiberghien et al., 2001; Zanzonico et al.,
2006). The tag must be expressed in the plasma membrane, and
it should be nonimmunogenic, preferably a human sequence.
The only gene-transfer-mediated cell surface tag to enter clinical
trials is a truncated form of the human nerve growth factor
receptor, used to enable selection of transduced T-lymphocytes
prior to transplantation to treat leukemia (Bonini et al., 2007).
Other gene-transfer-mediated cell surface tags that have been
assessed in preclinical models include CD20 and CD34 (Fehse
et al., 2000; Introna et al., 2000). Once a suitable tag is chosen,
it needs to be combined with an anti-tag monoclonal antibody
that can be administered in vivo, which will search out and
bind the tag with high specificity and affinity, carrying with it
a therapeutic agent that will destroy the tagged cells, preferably
without inducing pathology in the surrounding normal tissues.
Examples of ‘‘armed’’ monoclonal antibodies (‘‘immunotoxins’’)
that are highly selective for the targeted cell and carry weapons
that can mediate destruction of the cell include antibodies
with linked toxins (e.g., chemotherapeutic agents, radioactive
compounds) and antibodies with a linked prodrug enzyme
(Pastan et al., 2006; Schaedel and Reiter, 2006; Wu and Senter,
2005). In the latter case, the antibody delivers the prodrug-
activating enzyme into the target cell, and when the prodrug is
administered, its toxic effects are activated only within the milieu
of the tagged cell. In applying this strategy to eliminate wayward
stem cells, the monoclonal antibody would be specific for the
molecular tag genetically expressed in the transplanted cells
(e.g., anti-nerve growth factor receptor). The advantage of this
approach is that it is not dependent on the nonleaky promoters
used in the toxic gene strategy but is dependent on access of
the systemic or local administered monoclonal antibody or other
targeted therapy. Both approaches have similar risks regarding
bystander toxicity and potential immunogenicity.
Additional Requirements for Effective Control
In addition to choosing a promoter and effector gene, there are
three additional design requirements in order to ensure effective
and safe control over wayward stem cells posttransplantation:
integration, 100% modification, and lack of immunogenicity.
First, because pluripotent stem cells and many of their
progeny can proliferate, the genes(s) to be transformed must
be integrated into the cell genome, thus insuring that all daughter
cells of the transplanted population are genetically modified.
Two decades of gene therapy research has generated a variety
of vectors that serve as gene transfer delivery vehicles. The
vectors that have been used in human studies, and thus can
be readily translated to the stem cell clinic, include nonviral
vectors (naked plasmids and plasmids associated with lipo-
somes) and viral vectors (adenovirus, adeno-associated virus,
retrovirus, lentivirus, herpes simplex virus, and measles virus)
(O’Connor and Crystal, 2006; Templeton, 2008). Of these, only
retrovirus, lentivirus, and (as a rare event) plasmids meet therequirement of mediating integration of the transferred gene
into the target cell genome (Sinn et al., 2005). The retro- and lenti-
virus vectors are far more efficient than plasmids, but since the
genetic modifications are carried out ex vivo, and since the
target cells can be maintained and clonal populations selected
in culture, concerns regarding efficiency are minimized, and
thus plasmid delivery remains a viable option (Giudice and
Trounson, 2008). One issue that must be addressed, however,
is the site of integration of the transferred gene. Most available
vectors mediate integration into the target cell genome in
a random fashion, with the accompanying risk of insertional
mutagenesis should the transferred gene be located in the
vicinity of a tumor suppressor gene or oncogene (Nair, 2008;
Bonini et al., 2007; Hacein-Bey-Abina et al., 2008; Raki et al.,
2006). Technology does exist to allow control over the integra-
tion site, but the efficiency of these site-specific integration strat-
egies will have to be improved to be adaptable for routine use for
genetically modifying stem cell populations (Sinn et al., 2005; Wu
and Burgess, 2004). However, as discussed above, because the
genetic modifications are carried out ex vivo, therapeutic appli-
cations may afford sufficient time prior to transplantation to
assess the integration site, particularly if a single cell or small
numbers of cells are used as the starting material to generate
the population to be transplanted.
Second, 100% of the transferred cells must be genetically
modified. While this requirement is stringent and a challenge to
achieve, complete modification of the graft is critical, because
contaminationof the transplantedcellswithonlya fewunmodified
pluripotent stem cells, or reversion of only a few differentiated cell
progenitors to pluripotent stemcells, carries the risk of generating
tumors. The requirement for 100% genetic transduction of the
target cells is much easier to meet if the target cells are prolifer-
ating (i.e., the pluripotent stem cells or their proliferating progeny,
but not terminally differentiated cells), allowing the genetically
modified cells to be selected. No gene transfer vector available
is sufficiently efficient to ensure genetic modification of every
cell in the ex vivo culture (Templeton, 2008). To circumvent this
challenge, there are several selection strategies that can be em-
ployed to ensure that 100% of the cells are genetically modified,
with the choice of strategy dependent on the target population of
cells, the promoter, and the gene used to control the cell popula-
tion once it has been transplanted (Miccio et al., 2008; Orchard
et al., 2002; Scheidemann et al., 2008). Assuming that the genet-
ically modified cell population can be sufficiently amplified, the
easiest strategy is to select and expand a single cell clone that
has been genetically modified and appropriately expresses the
relevant gene (Kubo et al., 2004; Jung et al., 2007). An alternative
strategy is to transfer a gene that allows selection of the geneti-
cally modified cells, although the gene product and the selection
agent must be human compatible and nonimmunogenic (Schei-
demann et al., 2008). For example, the gene coding for the trun-
cated nerve growth factor receptor has been used successfully
to tag T-lymphocytes, permitting selection of the genetically
modified cells for treatment of leukemia (Bonini et al., 2007).
Third, the product of genetic modification cannot be immuno-
genic to the recipient. That is, a serious risk of integrating genetic
information into pluripotent stem cells and their progeny is
whether the expressed genes will induce host immunity against
the transplanted cells expressing the transferred gene. ThisCell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. 295
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enzyme prodrug therapy, as well as the genes used for endoge-
nous control (see above), as both nonhuman proteins or the
protein products of mutated or absent human genes may be
immunogenic. Unlike cancer gene therapy, during which eliciting
an immune response may be beneficial for tumor eradication,
immune responses may be detrimental to transplant survival.
The experience garnered to date from human gene therapy trials
reveals that whether a given transgene is immunogenic must be
determined largely by trial and error, with no hard and fast rules
that permit accurate predictions by the clinician, and thus must
be monitored closely. The most widely used suicide gene,
HSV-TK, is a viral protein and therefore potentially immunogenic.
However, based on the clinical trials using HSV-TK-modified
lymphocytes to control graft versus host disease, HSV-TK
therapy has been successfully exploited by appropriate design
taking into account the immune suppression of the patient and
kinetics of the transplanted cells (Traversari et al., 2007).
Regulatory Issues
Genetic medicines, whether they be stem cell therapies, gene
therapy, or as we propose here, combined stem cell and gene
therapy, all carry significant risk to the patient, and thus must
undergo rigorous regulatory review, at both the local and
national levels. Genetic modification of stem cells and their
progeny carries the additional risk of insertional mutagenesis,
particularly if the transferred gene randomly inserts in a location
relevant to control of proliferation. A famous example of this
danger was observed during ex vivo genetic therapy of SCID-
X1, in which gene integration led to oncogene activation and
consequent leukemia in some recipients (Hacein-Bey-Abina
et al., 2003). Alternatively, the product of the transferred gene
(e.g., a heterologous enzyme that converts an innocuous pro-
drug to a toxic drug) may be immunogenic, leading to immune-
mediated destruction of the transplanted cells (Riddell et al.,
1996; Berger et al., 2006). However, from a regulatory viewpoint,
the ‘‘drug’’ is the combined, final therapeutic product to be deliv-
ered to the patient, i.e., the genetically modified stem/progenitor
cells. It is this ‘‘packaged’’ product that must pass muster in
rigorous toxicology testing, and the balance of risks and efficacy
will be assessed as for any new drug. In this context, regulatory
hurdles are, in principal, no different from that of any new drug.
Ideally, genetically modified stem/progenitor cells will have qual-
ities that make them safer to use, and to help shift the risk/benefit
balance in favor of benefit to the patient. While the level of safety
standards specifically applied to the Geron study are not public,
given the public attention to this area, undoubtedly the imposed
standards are stringent and far above that lacking in some other
countries (Lau et al., 2008).
Future Directions
In most cases, stem cell therapy is designed to function in
a persistent fashion, based on the use of cells that have the
ability to self-sustain and/or expand their population. The built-in
longevity of such a paradigm represents a clear advantage to the
patient, by offering the potential to minimize the frequency of
interventions, or perhaps even leading to a cure. By the same
token, however, this paradigm also brings significant risks that
are distinct from all other therapies, because there is no control296 Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc.over the intervention subsequent to performing the transplant.
The technology of gene therapy offers an ideal toolbox to the
stem cell therapist for the design of control mechanisms to regu-
late the potent biologics that are transplanted. Studies with
experimental animals (Table 1) and clinical trials in cancer gene
therapy (Bonini et al., 2007; Raki et al., 2006), provide evidence
that, in principle, these strategies are feasible, although many
technical challenges will need to be overcome to achieve effi-
cient and safe control over transplantation of the progeny of
pluripotent stem cells. Ideally, wayward stem cells will be
controlled with two independent systems, i.e., using genetically
modified cells carrying switches that will either reverse pluripo-
tency or eliminate the cells, combined with another of the strat-
egies we have described. A dual system would greatly increase
the likelihood of controlling transplanted cells in a ‘‘failsafe’’
manner. Together with improving the strategies to control the
transplanted cells, it is also important to develop strategies to
control potential harm to normal tissues that destruction of the
transplant may cause. In addition to the ‘‘bystander’’ effect of
several of these therapies, elimination of uncontrolled pluripotent
cells may result in the destruction of all transplanted cells,
including the properly functioning ones, depending on the
strategy used. Therefore, selective promoters active in pluripo-
tent cells provide an ideal strategy to selectively affect the cells
that have escaped normal growth control.
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